Advancing Gene Therapy Delivery
For the inherited retinal disease (IRD) and broader genetic medicine communities, progress in delivery technology represents a critical piece of the puzzle. According to reports from FirstWord Pharma, Capsida Biotherapeutics announced that partner AbbVie has exercised an option to develop the first program emerging from their ongoing collaboration, triggering a $40-million licensing fee for Capsida.
Key Details of the Partnership Milestone
Under the terms of the agreement, AbbVie has opted in to develop an experimental gene therapy following promising results from primate studies. According to the source material, the therapy utilizes Capsida’s engineered adeno-associated virus (AAV) capsids to deliver an undisclosed payload intravenously. Primate data indicated that the approach achieved broad neuronal expression while successfully avoiding off-target effects in the liver and dorsal root ganglia.
While the initial 2021 partnership focused on central nervous system targets, the two companies expanded their collaboration in 2023 to include targets for eye diseases. Moving forward, AbbVie will handle all subsequent preclinical and clinical development for this specific asset, while Capsida will be responsible for manufacturing the intravenously administered product. Specific details regarding the target disease have not been publicly disclosed.
What This Means for Patients and Families
For patients and families affected by genetic conditions, advancements in viral vector engineering are closely watched. Traditional gene therapy delivery methods often face hurdles such as limited specificity and unintended off-target impacts. Technologies designed to improve precision delivery while minimizing exposure to organs like the liver remain an active area of investigation across the biotech sector.
Looking Ahead
The collaboration between Capsida and AbbVie continues to progress across its remaining discovery programs, with Capsida also eligible for additional development milestones and tiered royalties on future sales. As preclinical and IND-enabling studies move forward, the community awaits further disclosures from the partners regarding the specific clinical applications of these engineered delivery platforms.